Contract manufacturers have carved out a lucrative niche within the biopharma industry, and the value of their collective capacity and production agility was on full display during the COVID-19 ...
As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if ...
(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens ...
Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research ...
Hosted on MSN
Trump Announces Pfizer Drug-Pricing Deal, Company To Invest $70 Billion in US Manufacturing
President Donald Trump announced a deal with Pfizer (PFE) on Tuesday that includes steep drug price cuts and a $70 billion investment in domestic manufacturing facilities. Speaking at the White House, ...
Hosted on MSN
Why Pfizer Inc. (PFE) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom
We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other ...
Drugmaker Pfizer has agreed to lower drug costs and invest $70 billion in U.S. manufacturing under a deal struck with the Trump administration, President Donald Trump said Tuesday.The announcement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results